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Abstract
Neovascularization associated with diabetic retinopathy (DR) and other ocular disorders is a leading cause of visual
impairment and adult-onset blindness. Currently available treatments are merely palliative and offer temporary solutions.
Here, we tested the efficacy of antiangiogenic gene transfer in an animal model that mimics the chronic progression of
human DR. Adeno-associated viral (AAV) vectors of serotype 2 coding for antiangiogenic Pigment Epithelium Derived Factor
(PEDF) were injected in the vitreous of a 1.5 month-old transgenic model of retinopathy that develops progressive
neovascularization. A single intravitreal injection led to long-term production of PEDF and to a striking inhibition of
intravitreal neovascularization, normalization of retinal capillary density, and prevention of retinal detachment. This was
parallel to a reduction in the intraocular levels of Vascular Endothelial Growth Factor (VEGF). Normalization of VEGF was
consistent with a downregulation of downstream effectors of angiogenesis, such as the activity of Matrix Metalloproteinases
(MMP) 2 and 9 and the content of Connective Tissue Growth Factor (CTGF). These results demonstrate long-term efficacy of
AAV-mediated PEDF overexpression in counteracting retinal neovascularization in a relevant animal model, and provides
evidence towards the use of this strategy to treat angiogenesis in DR and other chronic proliferative retinal disorders.
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Introduction
Pathological retinal neovascularization is a feature of diabetic
retinopathy and other ocular disorders characterized by retinal
hypoxia [1]. The abnormal growth of blood vessels in the eye can
threaten vision through several deleterious complications, such as
intravitreal hemorrhage or retinal detachment. As in other tissues,
retinal angiogenesis depends on the balance between pro- and
anti-angiogenic factors. In retinal hypoxia there is a disruption of
such balance due to intraocular increases of proangiogenic
molecules, such as Vascular Endothelial Growth Factor (VEGF)
[2]. Therefore, a therapeutic approach could be designed aimed at
counteracting the disease-induced excess of angiogenesis stimula-
tors by increasing the intraocular concentration of angiogenesis
inhibitors. Intraocular gene transfer is an attractive strategy to
achieve this, as long-term protein expression has repeatedly been
reported in rodents [3], dogs and non-human primates [4] after a
single gene transfer to the retina. Moreover, three independent
clinical trials for an inherited form of blindness have recently
confirmed the feasibility and safety of ocular gene transfer in
humans [5–7].
Pigment epithelium-derived factor (PEDF) was originally
isolated from a human retinal pigment ephitelium (RPE) cell
culture [8] but has subsequently been reported to be expressed in
several other tissues [9]. In the eye, PEDF expression is regulated
by hypoxia in an opposite manner to VEGF [10]. Indeed, an
inverse correlation between vitreous PEDF and VEGF levels in
patients with diabetic retinopathy has been described [11,12].
Amongst its many reported actions, PEDF shows powerful
antiangiogenic properties, with specificity for newly formed vessels
[13]. PEDF has also been proven to be neuroprotective in animal
models of neuronal degeneration [14–16]. In addition, PEDF has
been reported to have anti-inflammatory properties [17].
To test the efficacy of PEDF in counteracting the retinal
neovascularization characteristic of diabetic retinopathy, we
established a gene therapy protocol based on the transfer to the
mouse retina of the human PEDF gene using adeno-associated
viral vectors of serotype 2 (AAV2), which efficiently transduce the
retina [18]. As a model of diabetes-like retinopathy and retinal
neovascularization we used transgenic mice overexpressing IGF-I
in the retina (TgIGF-I) [19,20]. Due to retinal IGF-I accumula-
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tion, these mice show increased levels of intraocular VEGF and
vascular alterations that progress from a non-proliferative
retinopathy to neovascularization that causes retinal detachment
[19,20]. This model offers advantages compared to other
commonly used models of retinal angiogenesis, such as the
ischemia-induced retinopathy model, also known as retinopathy of
prematurity model (ROP), in which vessels regress at approxi-
mately 3 weeks of age [21]. Although the ROP model has proven
successful for proof-of-concept studies, it has not allowed the
evaluation of the long-term efficacy of antiangiogenic gene transfer
in counteracting chronic neovascularization. In contrast, in the
IGF-I transgenic retinas, neovascularization occurs and worsens as
animals age [19,20]. This is a key aspect when evaluating therapies
for a chronic disease such as diabetic retinopathy, in which years
may go by between the onset of vascular alterations and the
appearance of pathological neovascularization.
Here we show that AAV2-mediated gene transfer leads to high
and sustained (up to 18 months) PEDF overexpression after a
unique intravitreal delivery of the vector to TgIGF-I mice. PEDF
treatment resulted in a reduction in intravitreal neovasculariza-
tion, capillary density, and incidence of retinal detachment. PEDF
also mediated the down regulation of VEGF in TgIGF-I-treated
retinas, contributing to the decrease of downstream effectors of
retinal neovascularization. Altogether, these results demonstrate
the long-term efficacy of AAV2-mediated PEDF gene transfer in
an animal model in which the development of retinal neovascu-
larization follows a disease progression that mimics the human
pathology.
Results
AAV2 mediated expression of PEDF in TgIGF-I retinas
The tropism of AAV2 vectors after intravitreal injection has
previously been described for wild-type mouse retina [3]. To
determine whether the pathological features of TgIGF-I retinas
[19,20] could alter the normal pattern of infection of AAV2
vectors, the expression of the reporter protein GFP was analysed
after intravitreal delivery of AAV2-GFP (6.26107 vg/eye) in which
the GFP gene was under the control of an ubiquitous promoter.
The majority of the cells on the retinal surface expressed GFP, as
shown in flat-mounted retinas (Figure 1A). The protein was also
detected in superficial axons, indicating the transduction of
ganglion cells whose axonal fibres converge to form the optic
nerve (Figure 1A, arrows). GFP was also detected in cells located
deeper in the retina (Figure 1B). Detailed immunostaining with
specific markers for each neuronal type demonstrated that
amacrine (calretinin positive) and horizontal cells (stained with
calbindin) were also transduced by AAV2 in IGF-I mice, but
neither bipolar cells(specifically detected with a PKCa antibody),
nor glial cells (S100 for astrocytes, glutamine synthetase for Mu¨ller
cells) expressed GFP (Figure 1C, D), probably due to the lack of
AAV2-specific receptors on their cell-surfaces. Collectively, the
data indicate that intravitreal injection of AAV2 results in efficient
transduction of TgIGF-I retinas.
It has been shown that AAV vectors allow stable and prolonged
gene expression in the retina of rodents and large animal models
[22]. Six week-old TgIGF-I mice received a single intravitreal
injection of 6.46108 vg of an AAV2 vector carrying the human
PEDF (hPEDF) cDNA. The contralateral eye was treated with a
null AAV2 vector, containing a non-coding expression cassette. A
steady level of expression of hPEDF was reached 2 months after a
single injection of the vector (Figure 2A). Six months after gene
transfer, hPEDF was detected by immunofluorescence in flat-
mounted retinas, showing a pattern of expression similar to that
observed in AAV2-GFP-injected retinas (Figure 2B). Human
PEDF was also detected by Western blot in retinal extracts 6
months after injection of the vector (Figure 2C). Retinal PEDF
levels presented more than 6-fold increase in comparison with
uninjected retinas (Figure 2C, right panel). Noticeably, non-PEDF
treated TgIGF-I mice also showed an increase in endogenous
retinal PEDF protein, which cross-reacted with by the antibody
directed against the human protein in Western blots. This suggests
that the upregulation of PEDF may be one of the mechanisms by
which non-treated transgenic eyes attempt to counteract the
proangiogenic stimulus present. The use, however, of the same
antibody to immunolabel PEDF in retinal cross-sections from
AAV2-null and AAV2-hPEDF injected eyes, verified that the
PEDF overexpressed in ganglion cells was AAV2-hPEDF vector-
derived (Figure 2D). Finally, the immunohistochemichal detection
of GFP and hPEDF in retinal cells of animals aged 12 and 18
months, respectively, that received a single injection of vector at
1.5 months of age, confirmed lifelong persistence of expression of
the gene of interest after AAV-mediated gene delivery to the
rodent retina (Figure 2E).
PEDF treatment inhibits neovascularization in TgIGF-I
eyes
The intraocular accumulation of IGF-I in our transgenic model
results in abnormal growth of neovessels in the vitreous cavity [19].
Figure 3A depicts an intravitreal vessel from a non-treated IGF-I
transgenic mouse. This completely formed vascular structure is
associated with tissue, likely part of a fibrotic inner limiting
membrane, attached to a profoundly altered area of the retinal
surface. The presence of fully formed vessels in the vitreous cavity
of transgenic IGF-I mice was further confirmed by staining with
CD105, a marker of endothelial cells [23], and Collagen Type IV,
a marker of vascular basement membrane (Figure 3B). Six-months
after treatment, AAV-injected eyes were also investigated for the
presence of intravitreal vessels. CD105+/Col-IV+ vascular struc-
tures were detectable in the vitreous cavity of all transgenic eyes
receiving AAV2-null empty vector (Figure 3C), but no vessels were
observed in the vitreous cavity of any of the contralateral eyes
treated with AAV2-PEDF (data not shown). Similarly, after PAS-
haematoxylin staining, no vessels were observed in the vitreous
cavity of the right, PEDF-injected eyes (Figure 4A), and the
quantification of intravitreal PAS+ cells revealed that hPEDF gene
delivery led to a striking reduction in the number of these cells,
likely vascular cells [21], with respect to the untreated contralateral
eye in all animals analyzed (Figure 4B). Two null-injected
transgenic eyes could not be analysed due to marked retinal
detachment that impeded the counting of PAS+ cells in the
vitreous cavity.
To quantify the inhibitory effects of hPEDF on the intraretinal
vasculature, we measured the retinal capillary density at 7.5
months of age by digital image analysis of fluorescein angiogra-
phies at high magnification (Figure 5A). TgIGF-I mice showed an
increment of 20% in capillary density in comparison with age-
matched wild-type (Wt) animals (Figure 5B). Six months after
treatment, transgenic retinas treated with hPEDF presented a
capillary density similar to that of healthy retinas. This suggested
that vector-mediated PEDF overexpression succeeded in counter-
acting the ongoing neovascularization process present in trans-
genic retinas without affecting stable pre-existing vessels.
Effects of PEDF overexpression on retinal detatchment
Retinal detachment can occur in advanced diabetic retinopathy
as a consequence of intravitreal neovascularization that traction-
ally detaches the neuroretina from the supporting pigment
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Figure 2. Long-term expression of hPEDF after single AAV2-mediated intravitreal gene delivery. (A) Time-course of hPEDF expression
after a single intravitreal delivery of AAV2-hPEDF. Quantitative real time PCR analysis with transgene-specific primers revealed that hPEDF expression
reached a plateau 2 months after a single injection of AAV2-hPEDF to 1.5-month-old TgIGF-I mice. hPEDF expression was undetectable in AAV2-null
injected contralateral retinas. Values are expressed as the mean6SEM of 3 animals/group. (B) Immunohistochemical detection of GFP (left panel) and
PEDF (right panel) in retinal flat mounts 6 months after a single intravitreal injection of AAV2-GFP or AVV2-hPEDF demonstrating the expression of the
exogenous transgenes. Whereas GFP is an intracellular protein that accumulates inside the cell, allowing the detection of the protein in neuronal
dendrites and axons, PEDF is rapidly secreted after production, resulting in a more diffusse staining. Scale bar: 33 mm (C) PEDF Western Blot in retinas
of transgenic treated mice. Wild-type, non-injected (N.I.) and AAV2-GFP-treated transgenic mice were used as controls. Values are expressed as the
mean6SEM of 4–6 animals/group. D) Immunodetection of human PEDF in AAV2- null (left panel) and AAV2-hPEDF (right panel) injected eyes verified
that the PEDF overexpressed in ganglion cells was of vector-derived. Original magnification: 206. (E) Left panel, inmunohistochemical detection of
GFP (intracellular protein) in a flat-mounted retina 12 months after a single injection of AAV2-GFP to a wild-type mouse. Right panels, hPEDF (secreted
protein) inmunodetection in paraffin-embedded eye sections 18 months after a single intravitreal injection of AAV2-hPEDF to TgIGF-I. Scale bars:
66 mm (left panel), 105 mm (right upper panel), 94 mm (right lower panel).
doi:10.1371/journal.pone.0041511.g002
Figure 1. Specific cell types transduced by intravitreal AAV2 in TgIGF-I retinas. (A) Retinal flat-mount immunostained for GFP showing
transduction of cells located on the surface of the retina. Arrows indicate GFP signal in axons, demonstrating transduction of ganglion cells. (B) GFP
detection in paraffin-embedded eye sections. Besides transduction of cells in the ganglion cell layer (GCL), there was, to a lesser extend, transduction
of cells of the Inner Nuclear layer (INL) (inset, arrows). (C) Double immunostaining for GFP and calretinin (amacrine neurons) showed that amacrine
cells located both in the surface of the retina as well as in the INL were transduced by AAV2-GFP. Bipolar cells, stained with an antibody against PKC-
a, do not show colocalization with GFP nor in the cell bodies localized in the INL (right inset) nor in the neuronal projections ending at the GCL (left
inset). Immunohistochemistry for calbindin, expressed in horizontal cells of the INL outmost layer (left inset) and in a subtype of amacrine cells located
in the INL and GCL (right inset), showing that both cell types are transduced by AAV2-GFP. (D) Double immunostaining for GFP and Glutamine
synthetase (Mu¨ller cells). No expression of GFP was observed in the Mu¨ller cells’ end feet processes at the retinal surface (right panel) or in the cell
bodies in the INL (left panel). Astrocytes (S100+), localized in the most superficial retinal layer and around blood vessels, were not transduced by
AAV2-GFP. Original magnification: 106 (A), 26 (B). Scale bar: 33 mm (C, left and central panel); 74 mm (C, right panel); 74 mm (D, left panel); 18 mm (D,
right panel).
doi:10.1371/journal.pone.0041511.g001
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epithelium leading to visual loss [24]. In agreement with the
inhibitory effect of hPEDF on preretinal neovascularization, six
months after vector injection the incidence of retinal detachment
was 83% for the AAV2-null-treated eyes while it was only of
16.5% for the AAV2-hPEDF-treated eye (Figure 6). These results
clearly indicate that hPEDF treatment, either directly or through
the inhibition of intravitreal neovascularization is very efficacious in
preventing retinal detachment, a sight-threatening complication.
PEDF overexpression leads to decreased VEGF levels in a
hypoxia-independent manner
VEGF is increased in the vitreous of patients with proliferative
retinopathy and also in animal models of retinal neovasculariza-
tion [2,25], including TgIGF-I mice [19,20]. VEGF concentration
was measured by ELISA in aqueous humour of WT and non-
injected TgIGF-I, AAV2-null and AAV2-hPEDF treated TgIGF-I
mice at 7.5 months of age. Samples obtained from non-injected
and AAV2-null injected TgIGF-I showed a 50% of increment in
VEGF levels with respect to Wt (Figure 7A). This increased VEGF
in transgenic mice was normalized 6 months after a single treat-
ment with AAV2-hPEDF (Figure 7A), which was consistent with
the inhibition of neovascularization observed (Figures 4A, B, 5).
Hypoxia-inducible factor 1a (HIF-1a) is the main regulator of
the hypoxic response and promotes neovascularization through
upregulation of VEGF [26]. When HIF-1a was analyzed in retinas
of TgIGF-I mice at different ages, an aproximately 2-fold increase
over Wt levels was observed in 7.5 month-old mice, which was not
evident in younger animals (Figure 7B). However, HIF-1a levels
remained unchanged six months after AAV2-hPEDF administra-
tion in TgIGF-I mice (Figure 7C), suggesting that PEDF inhibitory
actions on vascular growth were not mediated by a reduction in
HIF-1a.
Figure 3. Intravitreal neovessels in non-treated and AAV-null-treated 7.5 month-old TgIGF-I mice. (A) Representative image of PAS-
stained sections of transgenic eyes showing intravitreal vessels. Note the presence of fibrotic tissue associated to the vessel attached to the inner
limiting membrane of the retina, in an area where the retinal morphology appears altered. Wild-type eyes did not present vascular structures nor
fibrosis in the vitreous cavity. Original magnification: 206 (B) ColIV (basal membrane marker) and CD105 (EC marker) inmunostaining in the same
intravitreal neovessel depicted in (A) corresponding to a transgenic mouse aged 7.5 months. A clear CD105+ ring-shaped signal, indicating the
presence of a lumen, was surrounded by Collagen IV+ staining. Arrows indicate completely formed intravitreal neovessels. Arrowheads indicate a
blood vessel within the retina. Scale bar: 25 mm. (C) Representative image of the CD105+/Col-IV+ vascular structures (asterisks) present in the vitreous
cavity of AAV2null-injected eyes 6 months after delivery of the vectors. No such structures were observed in the contralateral PEDF-treated eyes (data
not shown). The dashed line indicates the limit between the retina and the vitreous. Scale bar: 25 mm (left pannel), 7.5 mm (right pannel). GCL, ganglion
cell layer; L, lenses, V, vitreous cavity, R, retina.
doi:10.1371/journal.pone.0041511.g003
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PEDF treatment reduces angiogenesis-related factors in
TgIGF-I eyes
Matrix metalloproteinases (MMPs) are collagen degrading
enzymes essential for the remodelling of the vascular basement
membrane during neovessel formation. Their expression has been
described to be regulated by several factors including VEGF [27].
Consistent with the angiogenic process, TgIGF-I mice had
increased intraocular activity of both MMP2 and MMP9 at 7.5
months of age (Figure 8A). Six months after vector injection, a
reduction in the activity of these gelatinases was observed in
aqueous humour samples from PEDF-treated mice but not from
AAV2-null injected mice (Figure 8A). This reduction in metallo-
proteinases activity probably reflected the normalization of ocular
VEGF observed in PEDF-treated animals.
In proliferative retinopathy, neovascularization may progress to
a fibrotic phase that has been associated with elevated vitreous
levels of Connective Tissue Growth Factor (CTGF) [28]. VEGF
directly upregulates CTGF expression in retinal vascular cells [29].
When CTGF protein levels were analyzed by Western blot,
TgIGF-I retinas showed an approximately 7-fold increase in this
Figure 4. Inhibition of intravitreal neovascularization by AAV2-hPEDF treatment. (A) Representative micrographs of PAS-haematoxylin
stained sections of the left (AAV2null-injected) and right (AAV2-hPEDF-injected) eyes from TgIGF-I mice 6 months after delivery of the vectors. Each
pair of images corresponds to one animal. Note the presence of completely formed neovessels (insets, asterisks) in the vitreous cavity of AAV2-null-
injected eyes. Endothelial cells stain strongly for PAS (inset, arrows) [21]. Original magnification 206 (B) Endothelial cells on the vitreal side of the
internal limiting membrane were counted in six non-consecutive sections per eye. AAV2-hPEDF treated eyes showed a striking reduction in the
number of intravitreal PAS positive cells when compared with their untreated contralateral eyes. Two null-injected transgenic eyes could not be
analysed due to marked retinal detachment that impeded the counting of PAS+ cells in the vitreous cavity. GCL, ganglion cell layer; INL, inner nuclear
layer; ONL, outer nuclear layer; L, lenses; V, vitreous.
doi:10.1371/journal.pone.0041511.g004
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growth factor when compared to Wt (Figure 8B). However, after 6
months of AAV2-hPEDF treatment CTGF levels were normalized
(Figure 8B). Thus, PEDF overexpression could be an effective way
of preventing neovascularization-related fibrosis.
Discussion
Effective treatment for sight-threatening retinal neovasculariza-
tion associated with diseases such as diabetic retinopathy
represents a significant unmet medical need. Given the long-term
nature of these processes, the assessment of new therapies requires
their testing in adequate animal models that follow the pattern of
disease progression over time that the human disease does. The
present study shows that retinal PEDF gene transfer mediated by
AAV vectors results in inhibition of neovascularization in TgIGF-I
mice up to 6 months after a single injection.
AAV vectors have extensively been used for retinal transduction
in several animal models [3,4] and in human subjects [5–7].
Provided an ubiquitous promoter is used to drive the expression of
an exogenous gene, the type of cell which will be transduced by a
viral vector (tropism) is specific to the vector serotype and depends
on the presence of receptors on the cell surface that mediate viral
attachment and entry [30,31]. Several serotypes of AAVs have
been isolated, which show different tissue and cell tropisms
allowing for purpose-based selection of vectors [32]. Our choice of
AAV2 was based on the ability of this vector to efficiently
transduce the cells located on the retinal surface [3], so that these
cells would secrete the therapeutic protein in close proximity to the
Figure 5. Inhibition of intraretinal neovascularization by AAV2-hPEDF treatment. (A) Representative images used for the quantitative
assessment of intrarretinal capillary density. Original magnification: 406. (B) Twenty high-magnification images of the capillary network that excluded
major vessels were taken per retinal angiography with fluorescein-conjugated dextran, and the area corresponding to the capillary area was
calculated using software tools as percentage of green area over total retinal area. Digital image quantification showed a significant increase in the
retinal capillary density in transgenic animals compared with Wt. Six months after a single treatment with AAV2-hPEDF transgenic retinas showed a
capillary density similar to that of Wt healthy retinas. N.I., non-injected. Values are expressed as the mean 6SEM of 7 animals/group. *P,0.05.
doi:10.1371/journal.pone.0041511.g005
Figure 6. PEDF gene delivery prevents retinal detachment in TgIGF-I. Areas of retinal detachment were identified histologically by the
presence of retinal folds. In most of the cases, infiltrating cells were observed in the subretinal space created around the detachment (left panel,
asterisks). Arrows indicate the monolayer of cells than constitute the Retinal Pigment Epithelium (RPE). Representative micrographs of the AAV-null
and AAV2-hPEDF injected eyes of the same animal are shown. The incidence of retinal detachment was reduced from 83% to 16.5% after PEDF
treatment (n = 6). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; L, lenses; V, vitreous; SRS, Subretinal space. Original
magnification: 106.
doi:10.1371/journal.pone.0041511.g006
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retinal vasculature. However, recent work published by Chen and
colleagues confirmed the role of the physiological conditions of a
tissue in creating specific molecular signatures that can influence
AAV vector tropism [33]. Thus, we studied AAV2 vector tropism
in our IGF-I transgenic model. As described for other murine
models [3], after intravitreal delivery of an AAV2-GFP, the
majority of the cells on the ganglion cell layer expressed the
protein, indicating that the intravitreal efficiency of AAV2 vectors
was not altered in young TgIGF-I mice. Despite their exposure to
the viral solution, glial cells were not transduced by AAV2, as
previously reported for healthy rodent retinas [3]. AAV2-hPEDF
transduction efficiency was similar to that of AAV2-GFP and
persisted throughout the animal’s life. Protein expression following
intravitreal injection of AAV vectors has been reported to last up
to 6 years in large animal models [4]. This long-lasting transgene
expression may result from the low immunogenicity of AAV
vectors together with the immune privilege present in the eye,
which attenuates immune responses that could limit gene transfer
efficacy [34]. Hence, one single injection of AAV2-hPEDF allows
stable expression of the therapeutic protein, thus avoiding the
potentially deleterious effects of periodic intraocular injections of
Figure 7. Effects of AAV2-hPEDF treatment on VEGF levels in a HIF-1a independent manner. (A) Detection by ELISA of increased
intraocular VEGF levels in both TgIGF-I and AAV2-null injected TgIGF-I mice. Levels normalized 6 months after AAV2-hPEDF treatment. (B) Time-
course of retinal HIF-1a expression in TgIGF-I mice. HIF-1a protein was increased in retinas of 7.5 months-old TgIGF-I, remaining unaltered in younger
animals. (C) AAV2-PEDF treatment did not affect HIF-1a expression 6 months after injection of the vector. N.I., non-injected. Values are expressed as
the mean 6SEM of 4–10 animals/group. ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.pone.0041511.g007
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therapeutic agents required for the treatment of chronic pathol-
ogies like diabetic retinopathy.
AAV-PEDF gene therapy has proved successful in other animal
models of ocular neovascularization, such as laser-induced
choroidal neovascularization [35] and oxygen-induced retinopa-
thy [36]. However, these models have an acute and early
regressive phenotype that does not make them ideal for long-term
evaluations, required when the target pathology has slow
development and chronic features, as diabetic retinopathy or
macular oedema. In contrast, in the model used in the current
study, the TgIGF-I model, retinal neovascularization develops
over time as animals age, and is a result of intraocular IGF-I and
VEGF lifelong accumulation [19,20]. Although the levels of
intraocular IGF-I in our model are high compared to values
reported in human proliferative DR (,40% vs ,2–5% of
circulating levels, respectively [37,38]), vascular alterations devel-
op slowly as animals age, despite the presence of the growth factor
from birth. Retinal capillary density is significantly increased in
our animal model at 7.5 months of age when compared with age-
matched Wt animals. Transgenic animals receiving AAV2-hPEDF
treatment at 1.5 months of age showed normalization of the
capillary density 6 months after gene transfer. Moreover, PEDF
treatment led to a striking decrease in the number of vascular cells
detected in the vitreous cavity of these mice, which was associated
with a marked reduction in the incidence of retinal detachment.
Altogether these data suggest that PEDF overexpression can
counteract the ongoing intraretinal and intravitreal neovascular-
ization that develops with age in TgIGF-I mice. Although PEDF
expression by ganglion cells in the foveal region is proposed to
define the foveal avascular area [39], the fact that the capillary
density in PEDF overexpressing retinas was similar to that of
healthy Wt retinas, and not less, agrees with published literature
supporting the notion that PEDF effects are restricted to newly
formed vessels and do not affect quiescent vessels in the adult
retina [13,35].
The molecular mechanisms through which PEDF exerts its
antiangiogenic actions still remain elusive. PEDF induces apop-
tosis of endothelial cells and inhibits their migration [40]. Recent
evidence suggests that PEDF action may be based on the
disruption of VEGF signalling, impairing its binding to VEGF-
R2 [41] or degrading VEGF-R1 [42]. TgIGF-I mice have
increased intraocular levels of VEGF [19,20], which were
normalized after hPEDF overexpression. This effect on VEGF
protein was independent of HIF-1a, a regulator of VEGF
expression under hypoxia [43], as indicated by the fact that the
level of this protein remained unaltered after hPEDF treatment.
Altogether, these observations suggest that PEDF may be acting by
either regulating VEGF expression or VEGF stability. In addition,
the ability of PEDF to regulate VEGF levels and inhibit
angiogenesis despite the presence of increased HIF-1a suggests
that overexpression of PEDF could inhibit neovascularization in
hypoxic environments.
Noteworthy, we found that PEDF treatment did not lead to
complete inhibition of VEGF; after months of continuous PEDF
expression VEGF levels in AAV-hPEDF-treated mice were similar
to those of Wt. Although short-term clinical studies suggest that
anti-VEGF therapies may have some beneficial effects in the
treatment of proliferative diabetic retinopathy (reviewed in [44])
Figure 8. PEDF overexpression downregulates the activity of VEGF- regulated factors. (A) Decreased MMP2 and 9 activity in aqueous
humour from TgIGF-I mice after AAV2-hPEDF treatment. (B) Transgenic mice showed increased CTGF accumulation in comparison with WT. CTGF
levels were reduced after 6 months of AAV2-hPEDF treatment, but not after AAV2-null injection. N.I., non-injected. Values are expressed as the mean
6SEM of 4–10 animals/group. *P,0.05.
doi:10.1371/journal.pone.0041511.g008
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results are not conclusive. Basal levels of VEGF may be crucial to
ensure the survival of retinal neurons and glial cells, as evidenced
by studies with intensive anti-VEGF therapies that underscored
the role of VEGF as a neuroprotective molecule [45]. In this
regard, we believe that PEDF might be a safer candidate, and our
results indicate that PEDF overexpression normalizes VEGF levels
to those found in healthy retinas. Thus, our study in an animal
model with slow-progression retinopathy reveals PEDF-gene
transfer as a potentially useful therapy for ischemic retinopathies,
which can target neovascularization without compromising
protective VEGF levels. This may be important for diseases, such
as diabetic retinopathy, which require lifelong treatment, and in
which retinal neuronal function is also compromised [46].
Furthermore, PEDF has been reported to have anti-inflammatory
and neuroprotective properties, which would be of added value to
its antiangiogenic potential [14–17].
VEGF is the main activator of the proangiogenic process and
regulates the expression of other factors implicated in neovessel
formation. Amongst them, MMP2 and MMP9 are responsible for
the ECM remodelling needed for retinal neovascularization [47].
Their activity is increased in TgIGF-I eyes and decreased after
hPEDF treatment, suggesting that VEGF signalling is also reduced
after PEDF overexpression. Furthermore, CTGF, another down-
stream effector of VEGF whose increase in retinopathy underlies
fibrotic processes associated with retinal angiogenesis [28], was
also normalized in AAV-hPEDF treated retinas. This anti-
fibrogenic activity has been previously reported after PEDF gene
transfer in kidney of diabetic rats [48] but never before for the eye.
Together, these results show that PEDF overexpression is able to
counteract the neovascularization process present in TgIGF-I
retinas by modulating the expression of angiogenesis-related
factors.
In summary, in this study we showed that PEDF was able to
counteract angiogenesis in an adult and chronic model of retinal
neovascularization after a single injection of AAV2-hPEDF,
instead of repeated administrations of the therapeutic agent. In
addition, AAV-mediated gene transfer of hPEDF to the eye results
in normalization of intraocular levels of VEGF and other pro-
angiogenic molecules. These findings suggest that AAV-hPEDF
treatment may represent an effective therapy for diabetic




CD1 heterozygous mice overexpressing IGF-I in the retina were
used.
Ethics statement
Animal care and experimental procedures were approved by
the Ethics Committee in Animal and Human Experimentation of
Universitat Auto`noma de Barcelona (UAB).
Vector production
Vectors were generated by helper virus-free transfection of
HEK293 cells (Q-Biogene, Montreal, Canada) with three
plasmids: (1) a vector plasmid carrying the expression cassette
flanked by the viral ITRs corresponding to AAV2; (2) a packaging
plasmid carrying the AAV2 rep and cap genes; and (3) a helper
plasmid carrying the adenovirus helper functions. The expression
cassette contained the ubiquitous CAG promoter (hybrid of CMV
early enhancer/chicken ß actin promoter), GFP or human PEDF
cDNA (provided by Dr. Susan Crawford, Northwestern Univer-
sity, Evanston, IL, USA) and WPRE element. Three days after
transfection, cells were collected and lysated. Viral particles were
purified by iodixanol gradient.
Vector administration
Under a dissecting microscope, 2 ml of viral solution were
delivered to the vitreous cavity of deeply anesthetized mice
(100 mg/kg ketamine/10 mg/kg xylazine) using a 10-mm 33-
gauge needle mounted on a 5 ml Hamilton syringe (Hamilton
Bonaduz AG, Switzerland). The needle was advanced through the
sclera near to the corneoscleral limbus. Pupils were previously
dilated with Tropicamide (Alcon Cusı´, El Masnou, Spain) and
antibiotic and anti-inflammatory drops (Tobradex, Alcon Cusı´, El
Masnou , Spain) were administered after the injection. Animals
showing signs of trauma or ocular bleeding after the injection were
excluded from the study.
RNA extraction and quantitative real-time PCR
Retinas were homogenized in 200 ml of Tripure and retinal
RNA was purified using RNeasy Mini Kit (QIAGEN Sciences,
Germantown, MD, USA). cDNA was synthesized with Tran-
scriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzer-
land). Quantitative real-time PCR was performed using Light-
CyclerH 480 SYBR Green I Master (Roche, Basel, Switzerland)
with hPEDF-specific primers: Fw-TACCGGGTGCGATC-
CAGCA and Rv-TGGGCTGCTGATCAAGTCA (Invitrogen,
Paisley, UK).
Histological analysis
Formalin-fixed paraffin-embedded eye sections were incubated
with anti-GFP (ab6673, Abcam, Cambridge, UK; diluted 1/300),
anti-calretinin (7699/4, Zymed Laboratories, Invitrogen, Paisley,
UK; diluted 1/100), anti-PKCa (P 5704, Sigma-Aldrich, St. Louis,
MO, USA; diluted 1/500), anti-calbindin (C 7354, Sigma-Aldrich,
St. Louis, MO, USA; diluted 1/5000), anti-glutamine synthetase
(G 2781, Sigma-Aldrich, St. Louis, MO, USA; diluted 1/500),
anti-S100 (Z 0311, DAKO, Glostrup, Denmark; diluted 1/500),
anti-CollagenIV (AB756P, Chemicon, Millipore, Billerica, MA,
USA, diluted 1/100) or anti-CD105 (BAF1320, R&D Systems,
Minneapolis, MN, USA; diluted 1/10). Whole-mount formalin-
fixed retinas were incubated with anti-GFP (diluted 1/300) or anti-
PEDF (AF1177, R&D Systems, Minneapolis, MN, USA; diluted
1/50). Periodic acid-Schiff (PAS) and hematoxylin staining was
performed in paraffin-embedded eye sections. Images were
obtained with a laser-scanning confocal microscope (TCs SP2;
Leica Microsystems GmbH, Wetzlar, Germany) or a Nikon
Eclipse 90i microscope (Nikon Instruments Inc., Melville, NY,
USA).
Protein analysis
For Western blot, retinas were homogenized in lysis buffer and
100 mg of retinal extract were separated by 12% SDS-PAGE.
Immunoblot was performed with anti-PEDF (AF1177, R&D
Systems, Minneapolis, MN, USA; working dilution 1/100), anti-
CTGF (ab5097, Abcam, Cambridge, UK; working dilution 1/50),
or anti-Tubulin (ab4074, Abcam, Cambridge, UK; working
dilution 1/500). Detection was performed using Immobilon
Western reagent (Millipore, Billerica, MA, USA). The pixel
intensity of the bands obtained was determined with GeneSnap
software for Gene Genius Bio Imaging System (Syngene,
Synoptics Ltd, Cambridge, UK) and the ratio protein content/
tubulin content was calculated for each sample to allow loading-
independent comparison. For VEGF detection in aqueous humor
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10 ml of sample were analysed with the Mouse VEGF ELISA kit
(QIA52, Calbiochem, EMD Biosciences, Inc., Gibbstown, NJ,
USA).
Assessment of Neovascularization
For retinal angiograms, animals received a tail vein injection of
50 mg/ml FITC-conjugated Dextran (Sigma-Aldrich, St. Louis,
MO, USA ). Ten minutes later, animals were sacrificed and retinas
were dissected, flat-mounted and fixed. Twenty images per retina
(406) were captured (Nikon Eclipse 90i, Nikon Instruments Inc.,
Melville, NY, USA) and capillary area was determined using NIS
Elements Advanced Research 2.20 software (Nikon Instruments
Inc., Melville, NY, USA). Pre-retinal vessels were analyzed in
PAS-stained eye sections [21]. The number of PAS+ intravitreal
endothelial cells, on the vitreal side of the internal limiting
membrane, was counted in 6 non-consecutive sections/eye.
Zymography
3 ml of aqueous humor were directly loaded into 12%
polyacrylamide running gels containing 0.1 mg/ml of porcine
gelatin (BioRad, Hercules, CA, USA). Gels were removed from
glass plates, rinsed and incubated in 1 M Tris-HCl pH 7.5, 0.5 M
CaCl2 for 18 h at 37uC. After incubation, gels were stained in
0.1% Coomassie Blue, 10% acetic acid, 10% isopropanol for 2 h
and then destained in 10% acetic acid, 10% isopropanol until the
bands were clearly visible.
Statistical analysis
Values are expressed as the mean 6 SEM. Differences between
groups were compared by unpaired Student t test. Differences
were considered statistically significant at P values less than 0.05.
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